Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Cdiff Test to detect Clostridium difficile (C. difficile) ...
Roche ($RHHBY) got an FDA OK for its rapid test for Clostridium difficile, picking up another regulatory gold star as it broadens its offerings on its cobas 4800 ...
A single Clostridium difficile infection presents an array of challenges for hospitals. A December 2015 study in the American Journal of Infection Control found C. difficile infections can increase ...
Roche Diagnostics welcomes the announcement by Public Health Minister, Jane Ellison, to introduce Human Papillomavirus (HPV) primary screening in England. Brigitte Fernandes-McAlear, Director, Roche ...
The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA ...
Roche Holdings AGRHHBY recently launched CE-IVD - the cobas MRSA/SA nucleic acid test. The test will be used on the cobas Liat System for the qualitative detection and differentiation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback